Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMCnyeso - Immunocore

Next Previous
X
Search
Drug Profile

IMCnyeso - Immunocore

Alternative Names: 3537142; bispecific NY-ESO-1- and LAGE-1A-specific TCR/anti-CD3; GSK-3537142; GSK01; GSK1; HLA- A*0201-restricted NY-ESO-1- and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule; NY-ESO-1; NY-ESO-1-ImmTAC; NY-ESO-ImmTAC

Latest Information Update: 02 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunocore
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 Apr 2021 Immunocore terminates a phase I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) (NCT03515551) (Immunocore pipeline, April 2021)
  • 13 Apr 2021 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, Canada (IV) (Immunocore pipeline, April 2021)
  • 15 Mar 2021 Phase I/II development is ongoing for Solid tumours in USA, United Kingdom, Canada (IV) (NCT03515551)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top